Allergy Therapeutics (LON:AGY) Announces Earnings Results

Allergy Therapeutics (LON:AGY) posted its earnings results on Tuesday. The company reported GBX (0.38) EPS for the quarter, Digital Look Earnings reports. Allergy Therapeutics had a positive return on equity of 227.10% and a negative net margin of 72.91%.The business had revenue of GBX 3,628 million for the quarter.

Allergy Therapeutics Price Performance

AGY remained flat at GBX 10.30 on Thursday. The company had a trading volume of 71,346 shares, compared to its average volume of 280,355. The company has a market capitalization of £652.25 million, a PE ratio of -12.26, a price-to-earnings-growth ratio of -30.70 and a beta of 0.83. The company has a debt-to-equity ratio of -213.13, a quick ratio of 1.48 and a current ratio of 1.28. The stock’s fifty day simple moving average is GBX 10.96 and its two-hundred day simple moving average is GBX 10.04. Allergy Therapeutics has a 12-month low of GBX 5 and a 12-month high of GBX 12.10.

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company focussed on the treatment and diagnosis of allergic disorders, including aluminium free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development include vaccines for grass, tree and house dust mite, and peanut allergy vaccine in pre-clinical development.